BMRN:NASDAQ
Biomarin Pharmaceutical Inc
$57.23
arrow_upward
+0.93%(+0.53) 1D
$57.23
0.00% (0.00)
bedtimeAfter hours
Closed: Nov 13, 4:00:01 PM GMT-5 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for BMRN...
Open
$56.86
High
$57.39
Low
$56.35
Mkt. cap
11.09B
Avg. vol.
2.53M
Volume
1.47M
52-wk high
$70.98
52-wk low
$49.26
EPS
-$0.10
Beta
0.21
Shares outstanding
193.70M
No. of employees
3K
Open
$56.86
High
$57.39
Low
$56.35
Mkt. cap
11.09B
Avg. vol.
2.53M
Volume
1.47M
52-wk high
$70.98
52-wk low
$49.26
EPS
-$0.10
Beta
0.21
Shares outstanding
193.70M
No. of employees
3K
News stories
From web sources and news partners
TradingView
·
2 days ago
BioMarin Pharmaceutical Hits $1 Billion Revenue Milestone, Advances Rare-Disease Pipeline
Yahoo Finance
·
2 days ago
BioMarin Pharmaceutical Inc. (BMRN) Stock Forecasts
Stocks Down Under
·
2 days ago
BioMarin Pharmaceutical (NDQ:BMRN): The Market Sees A Mature Slow-Growth Biotech, But Is It Missing The Next Growth Leg?
TradingView
·
2 days ago
BMRN: Record Q3 revenue and pipeline expansion set up key readouts through 2028
Profile
BioMarin Pharmaceutical Inc. is an American biotechnology company headquartered in San Rafael, California. It has offices and facilities in the United States, South America, Asia, and Europe. BioMarin's core business and research are in enzyme replacement therapies. BioMarin was the first company to provide therapeutics for mucopolysaccharidosis type I, by manufacturing laronidase. BioMarin was also the first company to provide therapeutics for phenylketonuria.
Over the years, BioMarin has been criticised for drug pricing and for specific instances of denying access to drugs in clinical trials. Wikipedia
About Biomarin Pharmaceutical Inc
CEOAlexander Hardy
Employees3.22K
FoundedMar 1997
HeadquartersSan Rafael, California, United States
SectorHealth Care
IndustryBiotechnology
Websitebiomarin.com